Using relative transcriptional levels of novel biomarkers under investigation such as PSMA and AR in liquid biopsies from patients with mCRPC prior to 177Lu-PSMA-therapy, this study points at a relation of the molecular diagnostic CTC footprint to tumor load measured by PSMA-PET-CT imaging. The gene discussed is FOLH1; the disease is neoplasm.